Kerbside

LONG POSITIONS

Indiamart Intermesh
BSE Code: 542726
CMP:Rs.2261.55

Indian mart is India’s largest online B2B marketplace, connecting buyers with suppliers. The price movement in this counter in the recent past has been very good, driven by decent. As per our sources, the stock price is expected to see a further upmove. Some well-known HNIs and big market punters have initiated long positions in the stock as they are expecting it to move in the northward direction. Therefore, the stock can be looked at for shortterm trading gain.

STOCK ACCUMULATION

City Union Bank
BSE Code: 532210
CMP:Rs.222.05

City Union Bank is one of the oldest private sector banks in the country. The main focus of the bank-lending to MSME, Retail/Wholesale Trade with granular profile including providing short term and long term loans to agricultural sector. There is a buzz in the market that bull operators and some of the well-known investors of D-Street are accumulating the stock. Technical indicators are also favoring the bulls, indicating extended bullishness. The stock is likely to head northwards and deliver good returns in the short term

FESTIVE SEASON

Berger Paints
BSE Code: 509480
CMP:Rs.449.80

Berger Paints: come festive season and our spending power suddenly sees a surge. Be it buying electronics, electrical consumer durables products or even furniture, home improvement items or for some, it is even the right time to put a new coat of paints to let the rooms dazzle keeping in tune with the festivities. All the while when we keep spending money for all these, stocks of companies producing these items also witness a rise. Our sources suggest that Berger Paint is one of the hot stocks to invest to play on this theme.

FOCUSED APPROACH

Metropolis Healthcare
BSE Code: 542650
CMP:Rs.1269.15

Metropolis Healthcare is one of the leading diagnostic chains in western India and focus cities (Mumbai, Pune, Chennai, Bangalore and Surat) contributed 50% plus of the company’s revenue in FY19. B2C segment now contributes 56% of the revenue from focus cities as compared to 51% in Q1FY19 & in FY19. Company is focusing on increasing its B2C business via aggressive network expansion, integrated brand building campaigns, building awareness amongst doctors for quality & services and focus on customer experience & improvement. The company has entered into a Public-Private Partnership (PPP) contract for three years with National Aids Control Organization (NACO) to collect specimens from government-owned antiretroviral therapy (ART) centers and conduct HIV-1 Viral load tests and this contract is expected to help company obtain additional PPP tenders in the future. 10 of 13 labs added in FY19 via lab on lease model which is asset with no capital requirement. A good stock to buy for the short-medium term.

(Closing price as of Oct 09, 2019)